Get the Stockscreener App
11.44
0.18%
0.02
Pre-market:
11.31
-0.13
-1.14%
Keros Therapeutics Inc Stock (KROS) Latest News
AlphaQuest LLC Purchases 2,964 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
(KROS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine (NASDAQ:KROS) - Seeking Alpha
Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade - MSN
Equities Analysts Set Expectations for KROS Q1 Earnings - MarketBeat
Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $42.33 - MarketBeat
FY2026 Earnings Estimate for KROS Issued By Leerink Partnrs - MarketBeat
HC Wainwright Issues Optimistic Outlook for KROS Earnings - MarketBeat
Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $42.33 - Defense World
Leerink Partnrs Has Bullish Outlook for KROS FY2026 Earnings - Defense World
Handelsbanken Fonder AB Boosts Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
HC Wainwright Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price - MarketBeat
Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $26.00 - MarketBeat
(KROS) On The My Stocks Page - Stock Traders Daily
Q1 EPS Forecast for Keros Therapeutics Lifted by Analyst - Defense World
What is William Blair’s Forecast for KROS Q1 Earnings? - Defense World
Keros Therapeutics (NASDAQ:KROS) Releases Earnings Results, Beats Expectations By $0.22 EPS - MarketBeat
Y Intercept Hong Kong Ltd Raises Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Q2 Earnings Estimate for KROS Issued By Leerink Partnrs - MarketBeat
Keros Therapeutics CEO to Speak at Major Conferences - TipRanks
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - The Manila Times
When and Where to Hear Keros Therapeutics' Latest Updates: CEO's March Conference Schedule - StockTitan
Keros Therapeutics Hold Rating: Uncertainty in KER-065 Development and Cibotercept Safety Concerns - TipRanks
Keros Therapeutics stock target cut to $40 at H.C. Wainwright By Investing.com - Investing.com South Africa
Analyst Expectations For Keros Therapeutics's Future - Benzinga
Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect - ACCESS Newswire
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Keros Therapeutics Strengthens Financial Position Amid R&D Expansion - TipRanks
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates - MSN
Keros Therapeutics, Inc. SEC 10-K Report - TradingView
Keros Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Keros Therapeutics reports Q4 EPS ($1.14) vs. ($1.34) last year - TipRanks
How Keros Therapeutics Secured Funding Until 2029 Despite Widening Losses - StockTitan
Keros Therapeutics (KROS) Projected to Post Earnings on Wednesday - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Sees Large Growth in Short Interest - MarketBeat
Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - Defense World
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - MSN
Institutional owners may consider drastic measures as Keros Therapeutics, Inc.'s (NASDAQ:KROS) recent US$55m drop adds to long-term losses - Simply Wall St
0.22%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):